Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 325295, 6 pages
http://dx.doi.org/10.1155/2011/325295
Clinical Study

Performance of a Whole-Blood Interferon-Gamma Release Assay with Mycobacterium RD1-Specific Antigens among HIV-Infected Persons

1Department of Pulmonary Medicine, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-shi, Tokyo 183-8524, Japan
2Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 18-22-3 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan
3The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose-shi, Tokyo 204-8533, Japan

Received 23 May 2010; Accepted 7 July 2010

Academic Editor: Katalin Andrea Wilkinson

Copyright © 2011 Akira Fujita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To evaluate the usefulness of one of IGRAs, QuantiFERON-TB Gold (QFT-G), in human immunodeficiency virus- (HIV- ) infected patients with various T cell counts. Methods. The QFT-G assay was performed using QFT-G kits among 107 HIV-infected patients including 9 cases with active tuberculosis (TB). Results. In HIV-infected patients with , QFT-G positive rate for active TB patients was 5/6 (sensitivity ), and that for those without active disease was 1/69 (specificity ). The frequency of indeterminate QFT-G test was significantly higher in those with less than ( ). At the same time there was a proportional relationship between and interferon-gamma response to mitogen (positive control) in QFT-G test ( ). Conclusions. Our data suggested that QFT-G had high sensitivity and specificity in HIV-infected populations with greater than . However, QFT-G did not perform well in HIV-positive patients with less than .